Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.

Ali Oğul Mehmet Mutlu Kidi Mahmut Buyuksimsek

Published in: Journal of gastrointestinal cancer (2021)

In patients with advanced BTC using GEMCIS as the first-line chemotherapy regimen, NLR and PNI can be used as prognostic inflammatory markers for 6-month PFS and 12-month OS.

Keyphrases

locally advanced
papillary thyroid
squamous cell
rectal cancer
radiation therapy
childhood cancer
newly diagnosed
young adults